News

ProtecT trial shows classical risk categories don’t help

EAU17: ProtecT trial shows classical risk categories don’t help

The classical risk categories used to stage prostate cancer disease do not aid clinical decision-making as much as PSA, biopsy, Gleason score, biopsy results and other measurements, according to an expert who commented during the Late-Breaking news segment of...

EAU17: Activating patients is key to enhanced recovery

Prof. James Catto (GB) was one of the closing speakers of the third Plenary Session at EAU17, speaking with great enthusiasm about the post-cystectomy ‘ERAS’ approach to patient care. Plenary Session 3 was mainly focused on bladder cancer and...

EAU17: Expert challenges expert

At Thematic Session 2, ‘Expert Challenges Expert,’ specialist surgeons presented opposing surgical treatments, aiming to provide either a critique or an alternative view of a standard procedure; a format which led to an engrossing session covering salvage prostatectomy and...

EAU17: Thematic Session explores personalised medicine in prostate cancer

Knowledge of overexpressed oncogenes and the importance of the transcription factor ETS-related gene (ERG) and cytokines in relation to individualised therapy in prostate cancer, were examined today during the “Personalised medicine in urological oncology” session chaired by Prof. Zoran Culig...

EAU17: Breakthroughs in andrology

New insights into the gold standards, developments and controversies within andrology were deliberated today in the state-of-the-art lectures of the “Hot topics in andrology” session chaired by Prof. Dr. Francesco Montorsi (IT) and Prof. Hein Van Poppel (BE). The...